ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2e3 years, although the range is wide, and survival may be longer for patients treated in specialized institutions. Implementation of current knowledge is highly variable among countries and within each country. The use of treatment guidelines has been associated with a significant improvement in survival. This has been achieved mainly in early breast cancer. For ABC, and particularly metastatic breast cancer (MBC), less level 1 evidence exists and only recently have international consensus guidelines been developed (ABC1 e). The ABC Consensus Conference was created by the European School of Oncology (ESO) with the ambitious goal of improving outcomes for all patients with advanced breast cancer. Backed by strong political advocacy, ABC guidelines are seeking to improve standards of care, to raise awareness about how to best meet to the needs of this underserved group of patients, and to identify research priorities so that clinical research is focused on the most important areas of unmet need. Following the work of the ESO-ABC Task Force, created in 2005, and the successful undertaking of the 1st International Consensus Guidelines Conference on ABC (ABC1), held in November 2011, the 2nd International Consensus Conference for Advanced Breast Cancer (ABC2) took place in Lisbon, Portugal, on
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For HER-2-positive LABC, anthracyclines should not be administered concurrently with trastuzumab since this approach does not increase the pCR rate, and it could increase the risk of cardiac toxicity, based largely on studies in the metastatic setting [35,36].”
BackgroundSelf-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 2×
“lapatinib plus capecitabine in the subset of 118 patients who were randomized in the first-line setting, having relapsed on or within 6 months of adjuvant trastuzumab, appeared similar to the effect seen in the overall trial [100].”
BackgroundResultSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“The mTOR inhibitor everolimus when added to exemestane, in patients progressing on non-steroidal aromatase inhibitor, provided a significant PFS prolongation of about 5 months [89,90].”
BackgroundSelf-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · cited 1×
“The CLEOPATRA trial [96,97]; showed superior results, in terms of PFS (18.”
ResultEarly palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62416-2 · Cited by 1,781 · cited 1×
“The multidisciplinary approach of ABC should encompass early in the history of the disease not only physical, but also functional, social, psychological, and spiritual, domains [25–27].”
BackgroundMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationGrading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220 · cited 1×
“Table 1 describes the grading system used [15].”
MethodCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094 · cited 1×
“Eribulin has provided an OS benefit in heavily pretreated patients (up to 5 lines of treatment) [115] and similar PFS and OS results to capecitabine after prior treatment with an anthracycline and taxane [116].”
ResultSelf-citationRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
Resultvon Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Research works printed but not linked: 2
- Handesman D Androgen Actions and Pharmacologic Uses, Endocrinology 2001 Philadelphia WB Saunders 2232 2242
- Wildiers H Kim SB Gonzalez-Martin A T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice 2013 Presented at the European Cancer Congress September 27–October 1 Amsterdam, The Netherlands (abstr LBA15)
Cited by
Items 301–400 of 540
Cinieri, S., Chan, A., Altundağ, K., Vandebroek, A., Tubiana-Mathieu, N., Barnadas, A., Dodyk, P., Lazzarelli, S., Botha, M., Rauch, D., et al. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.06.014 · Cited by 12
Wu, S., Li, F., Chen, Y., Sun, J., Lin, H., Lin, Q., & He, Z. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2295-0 · Cited by 13
Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer
Lousberg, L., & Jérusalem, G. (2016) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s12443 · Cited by 12
Zhang, T., Feng, F., Zhao, W., Yao, Y., Tian, J., Zhou, C., Zang, C., Liu, C., Wang, X., & Sun, C. (2018) · Cancer Management and Research · doi:10.2147/cmar.s176172 · Cited by 13
You, S. H., Chae, B. J., Eom, Y. H., Yoo, T.-K., Kim, Y., Kim, J. S., & Park, W. C. (2018) · Journal of Breast Cancer · doi:10.4048/jbc.2018.21.e53 · Cited by 13
The evolving role of receptors as predictive biomarkers for metastatic breast cancer
Martínez-Pérez, C., Turnbull, A., & Dixon, J. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1552138 · Cited by 16
“Current efforts are centered in improving survival and quality of life [96].”
BackgroundGoyal, R., Carter, G. C., Nagar, S. P., Smyth, E. N., Price, G. L., Huang, Y., Li, L., Davis, K. L., & Kaye, J. A. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1615422 · Cited by 12
Ciccarese, M., Fabi, A., Moscetti, L. I., Cazzaniga, M. E., Petrucelli, L., Forcignanò, R., Lupo, L. I., Matteis, E. D., Chiurì, V. E., Cairo, G., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4213-9 · Cited by 12
Steger, G. G., Domínguez, A., Dobrovolskaya, N., Giotta, F., Tubiana-Mathieu, N., Pecherstorfer, M., Ardizzoia, A., Błasińska-Morawiec, M., Espinosa, E., & Villanova, G. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.05.012 · Cited by 16
“In patients with hormone receptorepositive mBC, endocrine therapy is the preferred initial treatment unless there is proven endocrine resistance or rapidly progressing disease.(9) Often several lines of endocrine therapy can be given, but ultimately these options will be exhausted and an alternative strategy will be r…”
BackgroundTelford, C., Jones, N., Livings, C., & Batson, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.02.007 · Cited by 11
Crosstalk between triple negative breast cancer and microenvironment
Smrekar, K., Belyakov, A., & Jin, K. (2023) · Oncotarget · doi:10.18632/oncotarget.28397 · Cited by 13
Visceral crisis in metastatic breast cancer: an old concept with new perspectives
Andrade, M. D. O., Bonadio, R. C., Estevez-Diz, M. D. P., & Testa, L. (2024) · Clinics · doi:10.1016/j.clinsp.2024.100362 · Cited by 15
Noguchi, E., Yamanaka, T., Mukai, H., Yamamoto, N., Chung, C.-F., Lu, Y., Chang, D., Sohn, J., Kim, G. M., Lee, K.-H., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00684-w · Cited by 13
McCutcheon, S., & Cardoso, F. (2015) · The Breast · doi:10.1016/j.breast.2015.06.008 · Cited by 12
Self-citationPatients' experiences with decisions on timing of chemotherapy for breast cancer
de Ligt, K. M., Spronk, P. E. R., van Bommel, A. C. M., Peeters, M.-J. T. F. D. V., Siesling, S., & Smorenburg, C. H. (2017) · The Breast · doi:10.1016/j.breast.2017.10.016 · Cited by 12
Zhu, E., Zhang, L., Wang, J., Hu, C., Jing, Q., Shi, W., Xu, Z., Ai, P., Dai, Z., Shan, D., et al. (2024) · Cancer Innovation · doi:10.1002/cai2.119 · Cited by 11
Kümler, I., Balslev, E., Stenvang, J., Brünner, N., & Nielsen, D. L. (2015) · BMC Cancer · doi:10.1186/s12885-015-1072-9 · Cited by 11
“Although no specific recommendations are given in international guidelines regarding the choice of drug for second-or third line treatment, unanimously guidelines recommend sequential monotherapy [10,11].”
BackgroundThe Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer
Rossi, L., & Pagani, O. (2015) · Breast Care · doi:10.1159/000439462 · Cited by 11
Self-citationABC3 Consensus: Assessment by a German Group of Experts
Thomssen, C., Augustin, D., Ettl, J., Haidinger, R., Lück, H., Lüftner, D., Marmé, F., Marschner, N. W., Müller, L., Overkamp, F., et al. (2016) · Breast Care · doi:10.1159/000443515 · Cited by 11
Self-citationCarbognin, L., Sperduti, I., Ciccarese, M., Fabi, A., Petrucelli, L., Vari, S., Forcignanò, R., Nortilli, R., Vicentini, C., Pilotto, S., et al. (2016) · The Breast · doi:10.1016/j.breast.2016.06.021 · Cited by 11
“In this regard, a recent retrospective study showed that up to a quarter of patients with luminal ABC cancer started with chemotherapy in ‘real-life’ setting, whereas current guidelines recommend initial hormonal therapy for all luminal ABC patients, with the exception of patients with visceral crisis [4,34].”
BackgroundEffect of combinations of caffeine and caffeic acid on key enzymes linked to hypertension (in vitro)
Oboh, G., Adeoyo, O. O., Ademosun, A. O., Ogunsuyi, O. B., & Agunloye, O. M. (2018) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-018-0313-2 · Cited by 13
“The regulation of acetylcholinesterase as a therapeutic strategy for the management of cardiovascular diseases and hypertension has been established (Cardoso et al. 2014).”
Guo, Z., Tada, H., Kitamura, N., Hamada, Y., Miyashita, M., Harada-Shoji, N., Sato, A., Hamanaka, Y., Tsuboi, K., Harada, N., et al. (2019) · Cancers · doi:10.3390/cancers11040526 · Cited by 8
“Six-year DFS (6-DFS) was assessed to evaluate the correlation between biological factors and endocrine resistance (recurrence while on ET but after the first 2 years of ET or within a year after completion of 5-year adjuvant treatment) [5].”
BackgroundMethodBreast cancer screening: Impact on care pathways
Lefeuvre, D., Catajar, N., Bihan-Benjamin, C. L., Ifrah, N., BELS, F. D., Viguier, J., & Bousquet, P. (2019) · Cancer Medicine · doi:10.1002/cam4.2283 · Cited by 11
HORMONE-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER: DECISION MAKING IN REAL CLINICAL PRACTICE
Vladimirova, L. Y., Эдуардовна, С. А., Snezhko, T. A., Strakhova, L. K., Абрамова, Н. А., Kabanov, S. N., Kalabanova, E. A., Samaneva, N. Y., Svetitskaya, Y. V., & Викторовна, Т. А. (2020) · South Russian Journal of Cancer · doi:10.37748/2687-0533-2020-1-2-6 · Cited by 16
Pavlov, M. V., Петровна, Б. А., Plekhanov, V. I., Golubyatnikov, G. Y., Orlova, A., Subochev, P., Давыдова, Д. А., Turchin, I. V., & Maslennikova, A. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01607-6 · Cited by 12
“Before treatment, all patients were examined in accordance with the guidelines of the European Society for Medical Oncology (ESMO) [42] including mammography, ultrasound examination, and core biopsy of the tumor which provided the tumor receptor status.”
MethodGenerali, D., Montemurro, F., Bordonaro, R., Mafodda, A., Romito, S., Michelotti, A., Piovano, P., Ionta, M. T., Bighin, C., Sartori, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0461 · Cited by 11
“Endocrine therapy is an important class of target-directed therapy blocking the growth-promoting effects of estrogen via estrogen receptors (ER) [1].”
BackgroundCharacteristics, behaviour and role of biomarkers in metastatic triple-negative breast cancer
Goto, Y., Thike, A. A., Ong, C. C. H., Lim, J. X., Nasir, N. D. M., Li, H., Koh, V. C. Y., Chen, X.-Y., Yeong, J. P.-S., Sasano, H., et al. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2019-206078 · Cited by 12
Wang, J., Xu, B., Wang, W., Zhai, X., & Chen, X. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5047-9 · Cited by 11
Self-citationZhang, T., Feng, F., Zhao, W., Tian, J., Yao, Y., Zhou, C., Dong, S., Wang, C., Zang, C., Lv, Q., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s165681 · Cited by 9
“…was HR + (ER + and/or progesterone receptor-positive) postmenopausal women in ABC (inoperable locally ABC and metastatic breast cancer), 7 who had not received previous treatment for the advanced disease or had not received endocrine therapy as an adjuvant treatment within 12 months…”
Lux, M. P., Lewis, K., Rider, A., & Niyazov, A. (2022) · Future Oncology · doi:10.2217/fon-2021-1387 · Cited by 12
van Es, S. C., Venema, C. M., Glaudemans, A. W. J. M., Hooge, M. N. L., Elias, S. G., Boellaard, R., Hospers, G. A. P., Schroder, C. P., & de Vries, E. G. E. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157974 · Cited by 10
“Immunohistochemical (IHC) tumor staining for these receptors is considered to be the gold standard (4,30).”
BackgroundEvaluation of multiple transcriptomic gene risk signatures in male breast cancer
Bayani, J., Poncet, C., Crozier, C., Neven, A., Piper, T., Cunningham, C., Sobol, M., Aebi, S. P., Benstead, K., Bögler, O., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00301-0 · Cited by 9
Self-citationJérusalem, G., Neven, P., Marinsek, N., Zhang, J., Degun, R., Benelli, G., Saletan, S., Ricci, J.-F., & André, F. (2015) · BMC Cancer · doi:10.1186/s12885-015-1762-3 · Cited by 10
Self-citationSanchez, C. G., Mauricio Camus, A., Medina, L., David Oddó, B., Artigas, R., Pérez‐Sepúlveda, A., Domínguez, F., Razmilic, D., V, Navarro, M. E., Galindo, H., et al. (2016) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2016.17.12.5081 · Cited by 10
“While the receptor expression and differentiation may change over time in BC comparing primary tumor vs. relapse, most BC hold the initial expression pattern (Cardoso et al.,2014).”
BackgroundPatient Case Lessons: Endocrine Management of Advanced Breast Cancer
Robert, N. J., & Denduluri, N. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.05.014 · Cited by 11
“In premenopausal women, ovarian ablation or treatment with luteinizing hormone-releasing hormone analogues such as goserelin and leuprolide(11) may be used to suppress ovarian function.(12,13) For postmenopausal women, the nonsteroidal aromatase inhibitors (AIs) anastrozole and letrozole,(18,19) the steroidal AI exeme…”
BackgroundNgan, R. K. C. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.11 · Cited by 11
Imoto, S., Wang, K., Bi, X., Liu, G., Im, Y., Im, S., Sim, S. H., Ueno, T., Futamura, M., Toi, M., et al. (2023) · Breast Cancer · doi:10.1007/s12282-023-01436-7 · Cited by 11
“The aim of systemic therapy is first to prolong the patient’s survival, second to relieve the patient’s symptoms, and third to improve the patient’s quality of life [10].”
BackgroundSaghir, N. S. E., Kreidieh, F., El-Baba, S., & Anderson, B. O. (2016) · Breast Cancer Management · doi:10.2217/bmt-2016-0012 · Cited by 9
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients
Poggio, F. B., Lambertini, M., Blondeaux, E., Vaglica, M., Levaggi, A., Pronzato, P., & Mastro, L. D. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1215243 · Cited by 9
“mutations in the ESR1 gene that encodes the ER [4].”
BackgroundGarly, R., Berg, T., Jensen, M., Knoop, A. S., Volmer, L. M., Glavicic, V., Khan, H., Poulsen, P. B., Olsen, J., & Kümler, I. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2194030 · Cited by 9
“[20], AI and high-dose fulvestrant were treated as equivalent”
MethodBreast Cancer Is Our Global Responsibility
Harbeck, N., Gnant, M., & Thomssen, C. (2015) · Breast Care · doi:10.1159/000443159 · Cited by 11
Self-citationWalzer, S., Ponzetti, C., Canciani, M., Farina, M., & Era, S. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s97323 · Cited by 9
Kawahara, T., Shimozuma, K., Shiroiwa, T., Hagiwara, Y., Uemura, Y., Watanabe, T., Taira, N., Fukuda, T., Ohashi, Y., & Mukai, H. (2017) · Oncology · doi:10.1159/000484142 · Cited by 9
Rugo, H. S., Dieras, V. C., Cortés, J., Patt, D. A., Wildiers, H. P. M. W., O’Shaughnessy, J., Zamora, E., Yardley, D. A., Carter, G. C., Sheffield, K. M., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05838-5 · Cited by 10
Self-citationQuan, M., Oh, Y., Cho, S., Kim, J. H., & Moon, H. (2022) · Journal of Breast Cancer · doi:10.4048/jbc.2022.25.e28 · Cited by 11
“Among the clinical breast cancer subtypes, the triple-negative breast cancer (TNBC) subtype represents more aggressive tumors with a high risk of recurrence and deaths [4,5].”
BackgroundInfluentialJohnsson, A., Kiani, N. A., Gernaat, S. A. M., Wilking, U., Shabo, I., & Hedayati, E. (2023) · Cancer Medicine · doi:10.1002/cam4.5752 · Cited by 10
Romero, P. M., & Gil, R. M. (2015) · PubMed · doi:10.7399/fh.2015.39.3.8912 · Cited by 9
“2015;39(3):171-175 PALABRAS CLAVE Cáncer de mama; Trastuzumab emtansina; Coste-efectividad; Lapatinib”
BackgroundArpino, G., Marmé, F., Cortés, J., Ricevuto, E., Leonard, R. C., & Llombart‐Cussac, A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.007 · Cited by 9
Systemic Treatment for Breast Cancer: Chemotherapy and Biotherapy Agents
Bourdeanu, L., & Liu, E. A. (2015) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2015.02.003 · Cited by 10
Beith, J. M., Burslem, K., Bell, R. H., Woodward, N. E., McCarthy, N., BOER, R. D., Loi, S., & Redfern, A. D. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12491 · Cited by 9
Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?
Catania, G., Malaguti, P., Gasparro, S., Cognetti, F., Vidiri, A., & Fabi, A. (2018) · Oncology · doi:10.1159/000489066 · Cited by 8
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
Nardin, S., & Mastro, L. D. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-6266 · Cited by 8
Aromatase inhibitors in premenopause: Great expectations fulfilled?
Torrisi, R., Rota, S., Losurdo, A., Zuradelli, M., Masci, G., & Santoro, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.009 · Cited by 8
Bevacizumab: the phoenix of breast oncology?
André, F., Deluche, É., & Bonnefoi, H. R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70201-9 · Cited by 8
Self-citationOhno, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.03.001 · Cited by 10
Loman, N., & Saal, L. H. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.10.58 · Cited by 8
“Today’s standard procedures comprise of repeated imaging, preferably using RECIST criteria, supported by conventional circulating tumor markers (16,17).”
MethodZhao, Y., Zheng, W., Zhuo, Y. D., Lu, Y., Ma, X., Liu, H., Zeng, Z., & Laird, G. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1372770 · Cited by 10
Singh, G., Khare, S., Singh, S., Irrinki, S., Sakaray, Y. R., Mittal, B., & Bal, A. (2018) · Indian Journal of Nuclear Medicine · doi:10.4103/ijnm.ijnm_77_18 · Cited by 8
“[3] 18F‑FDG PET/CT is now recommended as an acceptable alternative to CT chest and abdomen and bone scan for staging LABC.”
BackgroundPatel, P., & Agrawal, Y. K. (2019) · Drug Delivery Letters · doi:10.2174/2210303109666190102115814 · Cited by 9
ABC4 Consensus: Assessment by a German Group of Experts
Harbeck, N., Lüftner, D., Marschner, N. W., Untch, M., Augustin, D., Briest, S., Ettl, J., Haidinger, R., Müller, L., Müller, V., et al. (2018) · Breast Care · doi:10.1159/000486722 · Cited by 8
Self-citationWallwiener, M., Nabieva, N., Feißt, M., Fehm, T. N., Waal, J. D., Rezai, M., Baier, B., Baake, G., Kolberg, H., Guggenberger, M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5806-y · Cited by 10
“While, according to current guidelines, premenopausal women should receive tamoxifen as first-line therapy, aromatase inhibitors (AIs) or fulvestrant are preferred in postmenopausal metastatic breast cancer (MBC) patients [1, 2].”
Self-citationMicroenvironment of Cancer Stem Cells
Tanabe, S. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-12974-2_5 · Cited by 10
Breast cancer immunotherapy: a comprehensive review
Keshavarz, S., Wall, J. R., Keshavarz, S., Vojoudi, E., & Jafari-Shakib, R. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01177-z · Cited by 9
“The latter two types are currently incurable, but treatable [8].”
Puglisi, F., Bisagni, G., Ciccarese, M., Fontanella, C., Gamucci, T., Leo, L., Molino, A., Silva, R. R., & Marchetti, P. (2016) · Future Oncology · doi:10.2217/fon-2016-0295 · Cited by 8
Ouldamer, L., Bendifallah, S., Chas, M., Boivin, L., Bédouet, L., Body, G., Ballester, M., & Daraï, É. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.039 · Cited by 8
Joining Forces: Establishing a Cardio-oncology Clinic
Austin-Mattison, C. (2018) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2018.9.2.8 · Cited by 8
“No randomized control trials were used to determine approaches (Cardoso et al., 2014).”
MethodCan antioxidant vitamins avoid the cardiotoxicity of doxorubicin in treating breast cancer?
Cavalcanti, I. D. L., Soares, J. C. S., Medeiros, S. M. D. F. R. D. S., Cavalcanti, I. M. F., & Nogueira, M. C. D. B. L. (2021) · PharmaNutrition · doi:10.1016/j.phanu.2021.100259 · Cited by 9
ABC3 Consensus Commented from the Perspective of the German Guidelines
Untch, M., Augustin, D., Ettl, J., Haidinger, R., Harbeck, N., Lück, H.-J., Lüftner, D., Marmé, F., Müller, L., Overkamp, F., et al. (2016) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0042-101168 · Cited by 8
Self-citationCiruelos, E., Vidal, M. J., de Dueñas, E. M., Martínez-Jáñez, N., Fernández, Y., García-Sáenz, J. Á., Murillo, L. S., Carabantes, F., Beliera, A., Fonseca, R., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1784-1 · Cited by 7
da Silva, F. C. N., Arboit, É. L., & Menezes, L. P. (2020) · Revista de Pesquisa Cuidado é Fundamental Online · doi:10.9789/2175-5361.rpcfo.v12.7136 · Cited by 7
Distress and Psycho-Oncological Support for Patients With Advanced Breast Cancer
Travado, L., & Bastos, L. D. S. (2023) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2023.151555 · Cited by 12
Thallinger, C., Láng, I., Kuhar, C. G., Bartsch, R., Singer, C. F., Petruzelka, L. B., Melichar, B., Knittelfelder, R., Brodowicz, T., & Zielinski, C. C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2171-y · Cited by 7
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?
Miglietta, F., Dieci, M. V., Griguolo, G., Guarneri, V., & Conte, P. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.001 · Cited by 7
CYP19A1 gene expression in the peripheral blood of Brazilian women with breast cancer relapse
Barros-Oliveira, M. D. C., Costa-Silva, D. R., Campos-Verdes, L. C., Pereira, R. D. O., Silva, R. A., Borges, P. D. T. M., Sousa, E. B., Pinho-Sobral, A. L., Lopes‐Costa, P. V., dos Santos, A. R., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06978-z · Cited by 8
“Patients were classified according to their sensitivity to endocrino therapy (ET) based on 2nd international consensus guidelines for advanced breast cancer, developed by European School of Oncology and European Society of Medical Oncology [19], responsive to ET, when relapses occur after 2 years of adjuvant ET or res…”
MethodLuminal A breast cancer resistance mechanisms and emerging treatments
Anderson, D. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00010-3 · Cited by 16
Long, H., Hu, C., Prijatelj, V., & Weng, C. (2020) · Medicine · doi:10.1097/md.0000000000020808 · Cited by 7
“Clinically, endocrine therapy is the preferred first-line treatment option for hormone receptor (HR)positive/human epidermal growth factor receptor 2 (HER2)negative metastatic breast cancer (MBC).([4]) Palbociclib (PAL), an oral inhibitor of cyclin-dependent kinases (CDK4/6), is a first-inclass drug indicated for the…”
Male Breast Cancer: Imaging Considerations for Diagnosis and Surveillance
Thomas, M., Kashroom, H. A., Reddy, S., Zaccarini, D. J., & Willer, K. (2024) · Journal of Clinical Medicine Research · doi:10.14740/jocmr5169 · Cited by 8
“Compared to female breast cancer, male breast cancer has higher rates of estrogen and progesterone receptor expression and lower rates of human epidermal growth factor receptor 2 (HER2)-neu expression [26-28].”
Interventional oncology in breast cancer
Orsi, F. (2023) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13600 · Cited by 7
Cruz, M. R. D. S., Reinert, T., & Cristofanilli, M. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.965 · Cited by 7
Untch, M., Würstlein, R., Marschner, N. W., Lüftner, D., Augustin, D., Briest, S., Ettl, J., Haidinger, R., Müller, L., Müller, V., et al. (2018) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-0594-2243 · Cited by 7
Self-citationIwamoto, T., Fujisawa, T., Shien, T., Araki, K., Sakamaki, K., Sangai, T., Kikawa, Y., Takao, S., Nishimura, R., Takahashi, M., et al. (2020) · Breast Cancer · doi:10.1007/s12282-020-01095-y · Cited by 6
“These guidelines propose the following classification of ET sensitivity in HR-positive ABC based on the time from ET induction to progression [7]: patients with recurrence during the first two years after the induction of adjuvant ET or with progression during the first three months after the induction of first-line E…”
BackgroundInfluentialChe, W., Wang, Y., Wang, X., & Lyu, J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1000415 · Cited by 6
Physicians' Considerations for Repeat Biopsy in Patients With Recurrent Metastatic Breast Cancer
Shachar, S. S., Fried, G., Drumea, K. C., Shafran, N., & Bar‐Sela, G. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.10.006 · Cited by 6
Neoadjuvant endocrine therapy in breast cancer patients
Cardoso, R. L., Magalhães, A., & Fougo, J. L. (2017) · Porto Biomedical Journal · doi:10.1016/j.pbj.2017.03.007 · Cited by 8
Strategies to prevent brain metastasis
Soffietti, R., Pellerino, A., & Rudà, R. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000572 · Cited by 7
“The ASCO and ESMO Guidelines [64,65] do not recommend the routine surveillance with MRI in asymptomatic patients due to ‘a low quality of evidence’.”
MethodBeslija, S., Gojković, Z., Cerić, T., Abazović, A. M., Marijanović, I., Vranić, S., Mustedanagić–Mujanović, J., Skenderi, F., Rakita, I., Guzijan, A., et al. (2021) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2020.4846 · Cited by 10
“Resection of liver metastases is generally not recommended since studies have not demonstrated the benefit of local treatment versus systemic chemotherapy [6,7,19,20] and could only be considered in HER2-positive patients under the age of 50 with solitary metastasis <5 cm.”
BackgroundDermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Moghimi, M., & Khodadadi, K. (2021) · Case Reports in Oncology · doi:10.1159/000517819 · Cited by 6
Palliative systemic therapy for young women with metastatic breast cancer
Eng, L. G., Dawood, S. S., & Dent, R. A. (2015) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000163 · Cited by 6
“However, no guidelines exist in current practice regarding the optimal sequencing of therapies [38].”
BackgroundEditorial: Why are guidelines not followed in clinical practice?
Cardoso, F., & Gennari, A. (2016) · The Breast · doi:10.1016/j.breast.2016.12.004 · Cited by 6
Self-citationLi, J., Liu, Y., Jiang, Y., & Shao, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157322 · Cited by 5
Wang, N., Wang, K., Liu, Y., & Song, F. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.08.009 · Cited by 7
Twelves, C. J., Anthoney, A., Savulsky, C. I., Guo, M. D., Reyderman, L., Cresti, N., Семиглазов, В. Ф., Timcheva, C. V., Zubairi, I. H., Morrison, R., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0366-5 · Cited by 6
Ding, L., Yang, Y., Chi, M., Chen, Z., Huang, Y., Ouyang, W., Li, W., He, L., & Wei, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282221 · Cited by 7
Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
Артамонова, Е. В. (2016) · Tumors of female reproductive system · doi:10.17650/1994-4098-2016-12-2-35-45 · Cited by 6
Heo, M. H., Kim, H. K., Lee, H., Kim, J., Ahn, J., Im, Y., & Park, Y. H. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.226 · Cited by 5
“Aromatase inhibitors (AIs) and tamoxifen are standard therapeutic options in the first-line treatment of postmenopausal patients with hormone receptor-positive metastatic breast cancer (MBC) [1].”
BackgroundBozkaya, Y., Erdem, G. U., & Demirci, N. S. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218762626 · Cited by 5
“Firstline endocrine therapy preferred for postmenopausal patients is either AI or tamoxifen.(6,7) Trials and metaanalysis have shown that overall survival advantage was achieved with AI compared to tamoxifen.”
BackgroundKümler, I., Balslev, E., Stenvang, J., Brünner, N., Ejlertsen, B., Jakobsen, E. H., & Nielsen, D. L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5788-9 · Cited by 5
Electrochemotherapy for Breast Cancer
Campana, L. G., Galuppo, S., Marconato, R., & Matthiessen, L. W. (2017) · Springer eBooks · doi:10.1007/978-3-319-32886-7_126 · Cited by 5
Brown, K. A., Andreopoulou, E., & Andreopoulou, P. (2020) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2020.16.1.17 · Cited by 6
Jhaveri, K. L., Ulaner, G. A., & Dickler, M. N. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3082 · Cited by 5
Metadata
- Authors
- Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., & Winer, E.
- Affiliations
- Centro Champalimaud (PT)
- European School of Oncology (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Gdańsk Medical University (PL)
- Clinique de Genolier (CH)
- Institut Gustave Roussy (FR)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- Karolinska University Hospital (SE)
- Fondazione Sandro Pitigliani (IT)
- Duke University (US)
- Champalimaud Foundation (PT)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Peter MacCallum Cancer Centre (AU)
- BC Cancer Agency (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Université Pierre-et-Marie-Curie (FR)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- The University of Sydney (AU)
- Sheba Medical Center (IL)
- Dana-Farber Cancer Institute (US)
- University of Michigan (US)
- Europa Donna (GE)
- Istituto Oncologico della Svizzera Italiana (CH)
- Centre Jean Perrin (FR)
- Institut Jules Bordet (BE)
- University of California, San Francisco (US)
- Indiana University (US)
- Martin Luther University Halle-Wittenberg (DE)
- Cardiff and Vale University Health Board (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Cardoso, F.
- ORCID
- Cardoso, F.
- Costa, A.
- Norton, L.
- Senkus, E.
- Aapro, M.
- André, F.
- Barrios, C.H.
- Bergh, J.
- Biganzoli, L.
- Cardoso, M.J.
- Fallowfield, L.
- Francis, P.
- Gelmon, K.
- Giordano, S.H.
- Gligorov, J.
- Harbeck, N.
- Houssami, N.
- Hudis, C.
- Kaufman, B.
- Krop, I.
- Pagani, O.
- Partridge, A.
- Penault-Llorca, F.
- Piccart, M.J.
- Rugo, H.
- Sledge, G.
- Thomssen, C.
- Vorobiof, D.
- Vrieling, C.
- Xu, B.
- Winer, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 25
- Issue
- 10
- Pages
- 1871-1888
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4176456
- OpenAlex
- W2127287298
- Cited by
- 540
- References
- 143
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 15 · 2023: 23 · 2022: 20 · 2021: 24 · 2020: 38 · 2019: 37 · 2018: 57 · 2017: 107 · 2016: 124 · 2015: 84 · 2014: 2
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1878 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc-nd)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by-nc-nd)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- advanced breast cancer, metastatic breast cancer, treatment guidelines, HER2-positive breast cancer, luminal breast cancer, overall survival, quality of life, standard of care, unmet medical needs, research priorities
- MeSH terms
- Breast Neoplasms, Female, Humans, Treatment Outcome, Guidelines as Topic, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.